| 货号 | HB996016 |
|---|---|
| 品牌 | abinScience |
| 描述 | Coltuximab ravtansine (SAR3419) is an antibody-drug conjugate (ADC) targeting CD19 created by conjugating a derivative of the potent microtubule-acting cytotoxic agent, maytansine, to a version of the anti-CD19 antibody, anti-B4, that was humanized as an IgG1 by variable domain resurfacing. Four different linker-maytansinoid constructs were synthesized (average ∼3.5 maytansinoids/antibody for each) to evaluate the impact of linker-payload design on the activity of the maytansinoid-ADCs targeting CD19. Anti-CD19 humanized monoclonal antibody conjugated to DM4. |
| 种属反应性 | Human |
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 宿主 | Chimeric |
| 同种型 | IgG1-kappa |
| 表达系统 | Mammalian Cells |
| 种属 | Human |
| 克隆类型 | Monoclonal |
| 靶标 | CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4 |
| 内毒素水平 | Please contact with the lab for this information. |
| 纯度 | >95% as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| Accession号 | P15391 |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS, pH 7.4. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| 别名 | SAR3419, 1269764-99-9 |
| 背景 | Budoprutug is an anti-CD19 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001). • An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer., PMID:30680780 • CAR-T cell therapy., PMID:32586666 • A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases., PMID:37427592 • B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody., PMID:20605905 • Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials., PMID:34310745 • CD19-CAR trials., PMID:24667955 • Optimized CD19/CD22/CD3 antibody., PMID:36264591 • [Not Available]., PMID:30686355 • Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma., PMID:33035333 • Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells., PMID:30030295 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
SEC-HPLC detection for Research Grade Coltuximab.
7X24小时产品咨询热线：027--87433958(9:00-18:00)，或扫描下方产品专员二维码或在线留言
武汉东湖新技术开发区神墩四路666号研发楼B区3层东
24小时产品查询
扫一扫关注我们
专属渠道经理
